Eli Lilly – Medgate Today

Lilly’s tirzepatide superior to semaglutide in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

December 6, 2024

6:15 am

Participants using tirzepatide lost 22.8 kg and participants on semaglutide lost 15.0 kg SURMOUNT-5 compared tirzepatide, a dual GIP and GLP-1 receptor agonist, to semaglutide, a mono GLP-1 receptor agonist in adults living with obesity without diabetes Eli Lilly and Company (NYSE: LLY) today announced topline results

POST TAGS:

Booster shot improves immune response of chemotherapy patients

October 7, 2021

5:53 am

News Update

admin

A new study helps quantify the improved protection against COVID-19 achieved with a third booster dose of the vaccine from Pfizer Inc (PFE.N) and BioNTech SE in cancer patients who are undergoing chemotherapy. "Chemotherapy can weaken the ability of cancer patients to fight off infections and to

POST TAGS:

Celexa Eli Lilly GlaxoSmithKline's Pfizer Inc Zoloft

Lilly’s tirzepatide superior to semaglutide in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

POST TAGS:

Booster shot improves immune response of chemotherapy patients

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA